Before joining Arbor, he was in sales management with Cyberonics, Inc., a medical device company focused on neuromodulation therapies. Prior to joining Cyberonics, Josh served as Director of Marketing at LipoScience, Inc., a specialty diagnostics company and oversaw commercialization of the company's lead product. Josh began his career at Glaxo Welcome (now GlaxoSmithKline) where he held positions of increasing responsibility within sales and marketing divisions. Josh received an MBA from Wake Forest University and a BS in Management from North Carolina State University.
Mr. Disbrow stated, "I am excited to be joining the management team at Ampio. Ampio has made significant progress in advancing their lead drugs towards commercialization in a short period of time, and I look forward to bringing my experience and enthusiasm to the team. The Ampio story is compelling, and I hope to play a significant role in helping the company complete their pivotal clinical trials and achieve successful commercial launches of their lead drugs in the near future."
"We are gratified that Mr. Disbrow has agreed to join our company," said Ampio CEO Michael Macaluso. "We were searching for an individual that has been successful in both big pharma and entrepreneurial environments, has a proven track record in launching commercialization of new drugs, and building teams of professionals that attain company goals. Josh fits these criteria perfectly. We have great confidence in the underlying science behind our lead drugs, our pivotal clinical trials lie immediately ahead of us, and we believe Josh will play a major role in assuring that we will execute on our many commercial opportunities."
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new mo
Page: 1 2 3 Related biology technology :1
|SOURCE Ampio Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Champions Oncology Reports Financial Results for the Year Ended April 30, 20122
. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities3
. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™4
. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 20125
. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results6
. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm7
. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner8
. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference9
. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock10
. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference11
. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference